Burns J W & Co. Inc. NY Cuts Position in Johnson & Johnson (NYSE:JNJ)

Burns J W & Co. Inc. NY reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,390 shares of the company’s stock after selling 385 shares during the quarter. Johnson & Johnson makes up about 1.4% of Burns J W & Co. Inc. NY’s holdings, making the stock its 17th largest position. Burns J W & Co. Inc. NY’s holdings in Johnson & Johnson were worth $9,711,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Toth Financial Advisory Corp increased its stake in shares of Johnson & Johnson by 1.8% during the 1st quarter. Toth Financial Advisory Corp now owns 62,847 shares of the company’s stock worth $9,942,000 after purchasing an additional 1,091 shares during the last quarter. Independence Bank of Kentucky raised its stake in shares of Johnson & Johnson by 7.7% in the first quarter. Independence Bank of Kentucky now owns 22,524 shares of the company’s stock valued at $3,563,000 after buying an additional 1,616 shares during the period. Norris Perne & French LLP MI lifted its position in shares of Johnson & Johnson by 4.1% during the 1st quarter. Norris Perne & French LLP MI now owns 107,328 shares of the company’s stock valued at $16,978,000 after buying an additional 4,203 shares during the last quarter. S.E.E.D. Planning Group LLC grew its stake in shares of Johnson & Johnson by 16.8% during the 1st quarter. S.E.E.D. Planning Group LLC now owns 33,344 shares of the company’s stock worth $5,275,000 after acquiring an additional 4,797 shares during the period. Finally, Webster Bank N. A. raised its stake in Johnson & Johnson by 0.6% in the 1st quarter. Webster Bank N. A. now owns 51,953 shares of the company’s stock valued at $8,218,000 after acquiring an additional 285 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.16 on Friday. The company has a market capitalization of $351.76 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The business has a 50 day moving average of $148.14 and a 200 day moving average of $154.06. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the previous year, the firm posted $2.68 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Monday, June 17th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.